Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma

被引：0

作者：

Lian, Bin ^{[1
]}

Mao, Li Li ^{[1
]}

Cui, Chuan Liang ^{[1
]}

Chi, Zhi Hong ^{[1
]}

Si, Lu ^{[1
]}

Sheng, Xi Nan ^{[1
]}

Li, Si Ming ^{[1
]}

Tang, Bi Xia ^{[1
]}

Guo, Jun ^{[1
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8506

引用

页数：1

共 50 条

[31] Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial
Grob, J. J.
Jouary, T.
Dreno, B.
Gutzmer, R.
Hauschild, A.
Leccia, M. T.
Landthaler, M.
Asselineau, J.
Garbe, C.
Pehamberger, H. E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[32] High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon - Results of a prospective, randomized, controlled trial
Fontana, RJ
Walsh, J
Moyer, CA
Lok, ASF
Webster, S
Klein, S
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 34 (02) : 177 - 182
[33] Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients
Nicola Mozzillo
Paolo Ascierto
Clinical & Experimental Metastasis, 2012, 29 : 801 - 805
[34] Acute rhabdomyolysis associated with administration of high-dose interferon alfa-2b for high-risk melanoma
Ramirez, A. Vanegas
Fischer, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 50 - 50
[35] Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients
Mozzillo, Nicola
Ascierto, Paolo
CLINICAL & EXPERIMENTAL METASTASIS, 2012, 29 (07) : 801 - 805
[36] Tolerability of a adjuvant high-dose interferon alfa-2b:: 1 month versus 1 year -: A hellenic cooperative oncology group study
Gogas, H
Bafaloukos, D
Ioannovich, J
Skarlos, D
Polyzos, A
Fountzilas, G
Kalofonos, HP
Aravantinos, G
Tsoutsos, D
Panagiotou, P
Frangia, K
Petrakopoulou, T
Pectasides, D
ANTICANCER RESEARCH, 2004, 24 (3B) : 1947 - 1952
[37] A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (US Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
Tarhini, Ahmad A.
Lee, Sandra J.
Hodi, F. Stephen
Rao, Uma N. M.
Cohen, Gary I.
Hamid, Omid
Hutchins, Laura Fulper
Sosman, Jeffrey Alan
Kluger, Harriet M.
Sondak, Vernon K.
Koon, Henry B.
Lawrence, Donald P.
Kendra, Kari Lynn
Minor, David R.
Lee, Carrie B.
Albertini, Mark R.
Flaherty, Lawrence E.
Petrella, Teresa M.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.
Cui, Chuanliang
Lian, Bin
Si, Lu
Chi, Zhihong
Sheng, Xinan
Kong, Yan
Wang, Xuan
Tian, Hui
Mao, Lili
Bai, Xue
Tang, Bixia
Yan, Xieqiao
Li, Siming
Zhou, Li
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study
Du, Yu
Qi, Zhonghui
Liang, Xianbin
Dai, Jie
Wei, Xiaoting
Bai, Xue
Mao, Lili
Chi, Zhihong
Cui, Chuanliang
Lian, Bin
Tang, Bixia
Wang, Xuan
Chen, Yu
Guo, Jun
Si, Lu
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (01):
[40] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
Muggiano, A
Mulas, C
Fiori, B
Liciardi, G
Pintus, M
Tanca, L
Tedde, A
Turno, R
Desogus, A
MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7

← 1 2 3 4 5 →